DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MANNITOL 5% IN PLASTIC CONTAINER

« Back to Dashboard

Clinical Trials for Mannitol 5% In Plastic Container

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT00003062	Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 2	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effect of temozolomide in patients with progressive or recurrent stage IV non-small cell lung cancer, with or without brain metastases, who have not been treated for metastatic disease with chemotherapy.
NCT00004767	Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders	Completed	Johns Hopkins University	Phase 2	OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00004767	Phase II Study of Sodium Phenylbutyrate, Sodium Benzoate, Sodium Phenylacetate, and Dietary Intervention for Urea Cycle Disorders	Completed	National Center for Research Resources (NCRR)	Phase 2	OBJECTIVES: I. Assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.
NCT00111956	Effects of Tumor Necrosis Factor (TNF)-Alpha Antagonism in Patients With Metabolic Syndrome	Completed	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	N/A	Metabolic syndrome is associated with increased inflammatory cytokines and reduced adiponectin, that may be mediated in part by TNF production from abdominal fat. We reasoned that an anti-TNF agent would reduce C-reactive protein (CRP) and increase adiponectin, improving the inflammatory milieu associated with metabolic syndrome.

Clinical Trial Conditions for Mannitol 5% In Plastic Container

Condition Name

Condition Name for Mannitol 5% In Plastic Container
Intervention	Trials
Asthma	20
Cystic Fibrosis	9
Healthy	6
Traumatic Brain Injury	6

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Mannitol 5% In Plastic Container
Intervention	Trials
Asthma	16
Intracranial Hypertension	11
Brain Injuries	9
Fibrosis	9

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Mannitol 5% In Plastic Container

Trials by Country

Trials by Country for Mannitol 5% In Plastic Container
Location	Trials
United States	132
United Kingdom	39
Australia	30
Canada	28
Argentina	18

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Mannitol 5% In Plastic Container
Location	Trials
New York	17
Massachusetts	9
Oregon	8
Ohio	8
Minnesota	8

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Mannitol 5% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Mannitol 5% In Plastic Container
Clinical Trial Phase	Trials
Phase 4	33
Phase 3	26
Phase 2/Phase 3	4

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Mannitol 5% In Plastic Container
Clinical Trial Phase	Trials
Completed	81
Recruiting	35
Unknown status	18

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Mannitol 5% In Plastic Container

Sponsor Name

Sponsor Name for Mannitol 5% In Plastic Container
Sponsor	Trials
Pharmaxis	19
Northwell Health	6
OHSU Knight Cancer Institute	6

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Mannitol 5% In Plastic Container
Sponsor	Trials
Other	214
Industry	48
NIH	16

Export unavailable in trial.
Subscribe for complete access.